Xiamen Amoytop Biotech Co Ltd (688278) - Total Liabilities
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has total liabilities worth CN¥453.98 Million CNY (≈ $66.43 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Xiamen Amoytop Biotech Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Xiamen Amoytop Biotech Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 688278 asset base.
Xiamen Amoytop Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CRRC Corporation Limited
F:C2L
|
Germany | €333.48 Billion |
|
Shanghai Huace Navigation Technology Ltd
SHE:300627
|
China | CN¥1.64 Billion |
|
Hong Ri Da Technology Co. Ltd. A
SHE:301285
|
China | CN¥1.05 Billion |
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
India | Rs-141.97 Billion |
|
SEB SA
PA:SK
|
France | €6.13 Billion |
|
CoreCivic Inc
NYSE:CXW
|
USA | $2.02 Billion |
|
Orion Oyj A
HE:ORNAV
|
Finland | €726.20 Million |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥3.55 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Xiamen Amoytop Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Xiamen Amoytop Biotech Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xiamen Amoytop Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥497.10 Million ≈ $72.74 Million |
+3.63% |
| 2023-12-31 | CN¥479.69 Million ≈ $70.19 Million |
+32.89% |
| 2022-12-31 | CN¥360.96 Million ≈ $52.82 Million |
+37.29% |
| 2021-12-31 | CN¥262.91 Million ≈ $38.47 Million |
+36.70% |
| 2020-12-31 | CN¥192.33 Million ≈ $28.14 Million |
-15.00% |
| 2019-12-31 | CN¥226.27 Million ≈ $33.11 Million |
+8.52% |
| 2018-12-31 | CN¥208.51 Million ≈ $30.51 Million |
+35.51% |
| 2017-12-31 | CN¥153.86 Million ≈ $22.52 Million |
-6.46% |
| 2016-12-31 | CN¥164.49 Million ≈ $24.07 Million |
-- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.